HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound Adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 49, Issue 1, 2000, Pages 11-15

  Kunath, Klaus ^a   Kopečková, Pavla ^a,b   Minko, Tamara ^a   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Adriamycin; Antibody targeting; Cytotoxicity; Doxorubicin; Gene expression; HPMA copolymer drug conjugates; Multidrug resistance; OV TL16 antibody; Ovarian carcinoma

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; DRUG EFFECT; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; DOXORUBICIN; FEMALE; GENES, BCL-2; GENES, FOS; GENES, JUN; GENES, MDR; HUMANS; IMMUNOCONJUGATES; METHACRYLATES; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; POLYMERS; TUMOR CELLS, CULTURED;

EID: 0342316489     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(99)00033-8     Document Type: Article

References (10)

1. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Poly. Sci. 122:1995;55-123.
2. Omelyanenko V., Kopečková P., Prakash R.K., Ebert C.D., Kopeček J. Biorecognition of HPMA copolymer-Adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Pharm. Res. 16:1999;1010-1019.
3. Omelyanenko V., Gentry C., Kopečková P., Kopeček J. HPMA copolymer-anticancer drug-OV-TLl6 antibody conjugates. 2. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer. 75:1998;600-608.
4. Boerman L., Massuger K., Makkink C., Thomas P., Kenemans L. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anticancer Res. 10:1990;1289-1296.
5. Minko T., Kopečková P., Pozharov V, Kopeček J. HPMA copolymer bound Adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Contr. Rel. 54:1998;223-233.
6. Minko T., Kopečková P., Kopeček J. Chronic exposure to HPMA copolymer-bound Adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Contr. Rel. 59:1999;133-148.
7. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytry, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs, U.S. Patent 5 037 883 (1991).
8. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., Kopeček J. Antibody directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugates to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:1988;100-114.
9. Minko T., Kopečková P., Kopeček J. Comparison of the anticancer effect of free and HPMA copolymer-bound Adriamycin in human ovarian carcinoma cells. Pharm. Res. 16:1999;986-996.
10. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., Ulbrich K., Strohalm J., Subr V., Spreafico F., Grandi M., Ripamonti M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Contr. Rel. 19:1992;331-346.